Sep 15, 2022 / 01:10PM GMT
Travis Lee Steed - BofA Securities, Research Division - MD
(technical difficulty)
Robert J. W. ten Hoedt - Medtronic plc - Executive VP and President, Europe, Middle East, Africa Region & Asia Pacific
That is the de novo patients plus the deferred patients should all be treated then we're going to get this increase in productivity. That happened in Spain and Italy, but it didn't in France, in the U.K. and in Germany. So these big markets, they have massive staffing issues. And so we see production coming back to pre-COVID levels, but we -- they cannot handle to deferred patients wave that's coming at them. APAC has not seen any of the issues with staffing. So we are basically just back at the levels that we were before COVID.
Questions and Answers:
Travis Lee Steed - BofA Securities, Research Division - MDIn terms of procedural volumes, we're pretty much back at kind of pre-COVID levels, normalized volumes and that's the plan from here. Maybe as staffing eases, we could see some recovery.
Trustpilot
